Influenza B Virus

• Relieves after effects of flu or flu-like symptoms * See symptoms on front panel.

Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.

1. 1Fatigue4814%
2. 2Diarrhoea3510%
3. 3Pain349.8%
4. 4Malaise329.2%
5. 5Dyspnoea298.4%
6. 6Nausea298.4%
7. 7Headache267.5%
8. 8Dizziness257.2%
9. 9Weight Decreased246.9%
10. 10Pyrexia236.6%
11. 11Cough226.3%
12. 12Asthenia205.8%
13. 13Off Label Use205.8%
14. 14Anxiety195.5%
15. 15Arthralgia195.5%

Recent PubMed references pinned to Influenza B Virus as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• The Concurrent Identification of SARS-Cov-2 and Influenza A/B Viruses in Nasopharyngeal Swabs Using Multiplex Real-time PCR.
  Archives of Razi Institute · 2025 · Hannan K, Mohammad Ehsan Y, Seyed Hossein A, et al.
  PMID 42226984DOI 10.32598/ARI.80.5.3482
• Global influenza epidemiology after 2020: patterns of circulation, epidemic timing and duration, and implications for vaccination strategies.
  Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026 · Del Riccio M, Caini S
  PMID 42212418DOI 10.2807/1560-7917.ES.2026.31.21.2500743
• Determinants of hospitalization and pneumonia in influenza during the post-pandemic era: Role of influenza A+B coinfection.
  Diagnostic microbiology and infectious disease · 2026 · Aldemir Ö, Öz M
  PMID 42143944DOI 10.1016/j.diagmicrobio.2026.117466
• Amplified-free and rapid nucleic acid detection of respiratory viruses based on streptavidin-functionalized quantum dot microspheres and magnetic beads.
  International journal of biological macromolecules · 2026 · Yin B, Li J, Shan Y, et al.
  PMID 42128108DOI 10.1016/j.ijbiomac.2026.152521
• Peripheral blood double-negative T cells percentage as a reliable biomarker for the prediction and diagnosis of pneumonia in pregnant women with influenza.
  International immunopharmacology · 2026 · Huang L, Zhai H, Cen P, et al.
  PMID 42107893DOI 10.1016/j.intimp.2026.116785
• Retooling a novel influenza B hemagglutinin to redirect neutralizing antibodies against B/Victoria strains.
  Vaccine · 2026 · Carlock MA, Ross TM
  PMID 42105398DOI 10.1016/j.vaccine.2026.128674
• Enhanced immunogenicity and dose-sparing efficacy of self-amplifying RNA vaccines against seasonal influenza across subtypes.
  Emerging microbes & infections · 2026 · Huang M, Quan Y, Chen R, et al.
  PMID 42081324DOI 10.1080/22221751.2026.2668752
• Evaluation of the QuickFinder COVID-19/Flu/RSV antigen test for rapid simultaneous detection of SARS-CoV-2, influenza A/B viruses, and respiratory syncytial virus.
  Diagnostic microbiology and infectious disease · 2026 · Kim JA, Kang M, Yu HJ, et al.
  PMID 42070376DOI 10.1016/j.diagmicrobio.2026.117443

The 10 most recently updated of 268 ClinicalTrials.gov registrations naming Influenza B Virus as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
  Recruiting · Phase 1 · Phase 2 · Interventional · 50 enrolled · PEACHES BIOTECH
  NCT06684379updated 2026-06-10
• A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
  Completed · Phase 2 · Interventional · 776 enrolled · GlaxoSmithKline
  NCT07121192updated 2026-05-28
• High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
  Recruiting · Phase 2 · Interventional · 312 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT05947071updated 2026-04-21
• Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
  Active not recruiting · Interventional · 1,000 enrolled · University of Nebraska
  NCT05864118updated 2026-04-17
• BPL-1357 Against H1N1 Influenza Virus Challenge
  Recruiting · Phase 2 · Interventional · 129 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT07215858updated 2026-04-13
• Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  Completed · Phase 2 · Interventional · 42 enrolled · Jennifer Woyach
  NCT02518555updated 2026-04-06
• Nasopharyngeal Carriage of S. Pneumoniae
  Recruiting · Interventional · 25,760 enrolled · Association Clinique Thérapeutique Infantile du val de Marne
  NCT04460313updated 2026-03-19
• Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
  Recruiting · Phase 1 · Interventional · 45 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT06863142updated 2026-02-23
• A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
  Completed · Phase 1 · Phase 2 · Interventional · 991 enrolled · GlaxoSmithKline
  NCT06382311updated 2026-02-05
• Vaccine Responses in Patients With B Cell Malignancies
  Recruiting · Phase 4 · Interventional · 500 enrolled · National Heart, Lung, and Blood Institute (NHLBI)
  NCT05170399updated 2026-02-05

Frequently asked questions

What is Influenza B Virus used for?

According to FDA labeling, Influenza B Virus carries indications including: Relieves after effects of flu or flu-like symptoms * See symptoms on front panel.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.